Evogliptin for the treatment option for type 2 diabetes: an update of the literature.

Abstract

INTRODUCTION:

Dipeptidyl peptidase-4 (DPP-4) inhibitors have been the most widely used for type 2 diabetes (T2D) available worldwide since 2006. DPP-4 inhibitors exert their effects by inhibiting dipeptidyl peptidase-4 to increase the concentration of endogenous incretin hormones (incretin hormone analogues and incretin potentiators) and promote insulin secretion, thereby acting as a glucose regulator. Evogliptin is a new member of the DPP-4 inhibitor family with high selectivity and low risk of hypoglycemia, and extensive clinical data has been accumulated in its treatment of T2D since its introduction in October 2015.

AREAS COVERED:

This review summarized the recently reported studies associated with the pharmacokinetics, pharmacodynamics, safety and tolerability, and clinical application of evogliptin for managing T2D. We searched the MEDLINE and PubMed databases with the titles 'evogliptin' to identify all the information. The abstracts and posters of the annual meetings of ADA and EASD and clinicalTrials.gov. have been searched up to now.

EXPERT COMMENTARY:

Evogliptin is a potent, orally effective, and highly selective DPP-4 inhibitor that is not only indicated for the treatment of T2D but may also be beneficial to arterial inflammation and atherosclerosis, with good safety and tolerance.

• Authors: Ping Zou, Mingxing Guo, Jingbo Hu
• Journal: Expert review of clinical pharmacology (Expert Rev Clin Pharmacol) Vol. 15 Issue 6 Pg. 747-757 (Jun 2022) ISSN: 1751-2441 [Electronic] England
• PMID: 35815592 (Publication Type: Journal Article, Review)

Chemical References

• Dipeptidyl-Peptidase IV Inhibitors
• Hypoglycemic Agents
• Incretins

Topics

• Diabetes Mellitus, Type 2 (drug therapy)
• Dipeptidyl-Peptidase IV Inhibitors (adverse effects)
• Humans
• Hypoglycemia
• Hypoglycemic Agents (adverse effects)
• Incretins